February 9, 2017
Carolyn R. Bertozzi joins Eli Lilly
Eli Lilly has welcomed Carolyn R. Bertozzi, Ph.D., as a new member, of its board, starting on February 10, 2017, joining two committees of the board.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
February 9, 2017
Oxford BioTherapeutics appoints chairman, adds to the board
Oxford BioTherapeutics has appointed Bernd Seizinger as Chairman, and and Jean-Pierre Bizzari, M.D. as a non-executive director, calling it a significant strengthening of its oncology focused board.
February 9, 2017
PrEP Biopharm’s asthma study misses goal, but gives useful insights
PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.
February 9, 2017
Amryt’s first full year as a public company, Cathal Friel leaves board
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
February 9, 2017
Boiron buys Laboratoire Ferrier
Boiron has signed an agreement with Laboratoires Arkopharma to take over Laboratoire Ferrier, a subsidiary of Laboratoires Arkopharma.
February 9, 2017
Tetraphase antibiotic may reach up to $700 million in annual sales: CEO
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.
February 9, 2017
Sanofi, Regeneron can sell Praluent in the US during the appeal on Amgen’s patent claims
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
February 8, 2017
Bayer’s and Janssen R&D’s cardiac drug meets primary goals sooner then expected
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
February 8, 2017
Portola’s thrombosis drug under FDA’s priority review without advisory meeting
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.
February 8, 2017
GSK’s new products sales boost revenues, future demands
GlaxoSmithCline has posted net profit in the fourth quarter 2016 of £1,062 million and fully year £8,372, and turnover revenue growth of 6% with sales mounting to £27.9 billion, mainly driven by continued strong performance of new products.